”Orum has granted Vertex rights to conduct research using its TPD² approach to developing degrader-antibody conjugates (DACs), next-generation versions of antibody-drug conjugates (ADCs) which use antibodies to precisely deliver small molecule targeted protein degrader payloads to cancer cells and other targeted biological therapies.”
a new platform for ADC development….n... - Advanced Prostate...
a new platform for ADC development….no sorry, it’s DAC this time! not PCa related but hopefully soon
Written by
Maxone73
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
A NEW COMBINED DRUG PSMA-DOC HAS BEEN CREATED FOR THE TREATMENT OF PROSTATE CANCER!
drug Docetaxel for targeted delivery of plant venom to malignant cells with PSMA protein on its...
Livalo: A Safer Statin?
THE CYP450* SYSTEM,\\" it uses another enzyme or pathway that \\"is in conjugation with glucuronic...
Dangers of AR degradation through ARV-110 etc?
signaling through the over repression of the AR by use of ADT (Lurpon ) and ADI therapies (...
Is there any cancer treatment when your platelets are low?
dangerous. Any ideas for other treatments I could use? PSA is 251 and rising. Already had chemo,...
Tomotherapy side effects?
Chemo or clinical trial?
Lymph Node Methasizes
Now Undetectable PSA on BAT Regimen
